Ginsenoside F4Ginsenoside F4
MedChemExpress (MCE)
HY-N2503
181225-33-2
98.54%
4°C, protect from light *In solvent : -80°C, 6 months
-20°C, 1 month (protect from light)
Room temperature in continental US
may vary elsewhere.
Ginsenoside F4 (GF4), ginseng saponinis, isolated from notoginseng or red ginseng. Ginsenoside F4 (GF4) has inhibitory effect on human lymphocytoma JK cell by inducing its apoptosis. Ginsenoside F4 (GF4) inhibits matrix metalloproteinase 13 (MMP 13) expression in IL-1β-treated chondrocytes and blocks cartilage breakdown in rabbit cartilage tissue culture, shows therapeutic potential for preventing cartilage collagen matrix breakdown in diseased tissues.
Ginsenoside F4 inhibits JK cell proliferation with an IC50 value of 87.74 μM[1]. Ginsenoside F4 (8.15-130.38 μM) dose-dependently increases Bax expression but reduces Bcl-2 expression in human lymphocytoma JK cells[1]. Ginsenoside F4 (8.15-130.38 μM) induces apoptosis in human lymphocytoma JK cells to exhibit anti-tumor activity[1].
| | | |
| | | | | |
[1]. Chen B, et al. The apoptosis-inducing effect of ginsenoside F4 from steamed notoginseng on human lymphocytoma JK cells. Nat Prod Res. 2013
27(24):2351-4. [Content Brief]
[2]. Lee JH, et al. Ginsenosides from Korean red ginseng inhibit matrix metalloproteinase-13 expression in articular chondrocytes and prevent cartilage degradation. Eur J Pharmacol. 2014 Feb 5
724:145-51. [Content Brief]